Literature DB >> 28818550

Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.

Pascal Mouracade1, Julien Dagenais1, Jaya Sai Chavali1, Onder Kara1, Ryan J Nelson1, Matthew J Maurice1, Jeremy Reese1, Brian I Rini2, Jihad H Kaouk3.   

Abstract

INTRODUCTION: We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC).
MATERIALS AND METHODS: Data were recorded from the consecutive records of patients who had undergone underwent PN for cT1-T2 RCC from 2007 to 2016. Of these patients, 143 had stage pT3a with SFI or PFI found on final pathologic examination. The demographic, perioperative, and pathologic variables were reviewed. DFS and CSS analyses were performed. The factors predicting disease progression in this population were assessed.
RESULTS: After a median follow-up period of 28 months (range 15-41 months), 19 patients (13.3%) had developed recurrence, including 5 local and 14 distant metastases, with 11 cancer-specific deaths (7.7%). No differences were found in DFS (5 years, 60.9% vs. 55.3%; log-rank P = .7) or CSS (5 years, 81% vs. 74.2%; log-rank P = .8) between the SFI and PFI groups. For the pT3a fat invasion population, the 2- and 5-year DFS and CSS rates were 83.6% and 58.6% and 93.6% and 78%, respectively. SFI (P = .5) and positive surgical margins (P = .1) did not predict for progression. On multivariate Cox regression, increased tumor size (hazard ratio, 1.5; 95% confidence interval, 1.1-1.9; P < .01) and higher tumor grade (hazard ratio, 3.6; 95% confidence interval, 1.1-4.6; P = .04) were independent predictors of disease progression in the pT3a fat invasion population.
CONCLUSION: In our series of patients with pT3a RCC after PN, SFI compared with PFI was not associated with an increased risk of progression or cancer-specific death.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Outcome; PFI; Renal cell carcinoma; SFI; Survival

Mesh:

Year:  2017        PMID: 28818550     DOI: 10.1016/j.clgc.2017.07.019

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  6 in total

1.  Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014.

Authors:  Jae Heon Kim; Shufeng Li; Yash Khandwala; Kyung Jin Chung; Hyung Keun Park; Benjamin I Chung
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

2.  National trends of preoperative imaging modalities before partial nephrectomy for renal masses in the U.S. from 2007-2015.

Authors:  Jae Heon Kim; Shufeng Li; Yash Khandwala; Francesco Del Giudice; Kyung Jin Chung; Hyung Keun Park; Benjamin I Chung
Journal:  Can Urol Assoc J       Date:  2018-08-30       Impact factor: 1.862

3.  Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma.

Authors:  Gu-Shun Lai; Jian-Ri Li; Shian-Shiang Wang; Chuan-Shu Chen; Chun-Kuang Yang; Sheng-Chun Hung; Chen-Li Cheng; Yen-Chuan Ou; Kun-Yuan Chiu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Association of Extrarenal Invasion Patterns and Tumor Size with the Differences in Survival Outcomes of T3a Renal Cell Carcinoma: A Proposal Modified T3a Stage System is Needed.

Authors:  XiaoFei Wu; Qiong Wang; Zhixian Wang; Xian Zhao; XiaoJing Xu
Journal:  Int J Gen Med       Date:  2022-01-07

5.  Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma.

Authors:  Jong Jin Oh; Jung Keun Lee; Byung Do Song; Hakmin Lee; Sangchul Lee; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

6.  Prognostic significance of the sub-classification of stage pT3a renal tumors by perinephric and sinus fat invasion.

Authors:  Dongsheng Zhu; Jingyuan Cao; Chao Zhi; Tao Guo; Yuhong Li; Zhiqiang Lang; Gang Li
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.